comparemela.com

Latest Breaking News On - Galecto inc - Page 2 : comparemela.com

GB2064 Displays Preliminary Efficacy, Tolerability in Myelofibrosis

The potential first-in-class, oral, lysyl oxidase-like 2 inhibitor GB2064 displayed efficacy with a generally acceptable tolerability profile in the treatment of patients with myelofibrosis.

Galecto (NASDAQ:GLTO) Trading Up 1 8%

Galecto, Inc. (NASDAQ:GLTO – Get Free Report)’s stock price was up 1.8% during mid-day trading on Monday . The stock traded as high as $0.73 and last traded at $0.72. Approximately 579,002 shares traded hands during mid-day trading, an increase of 89% from the average daily volume of 307,100 shares. The stock had previously closed […]

Nike, AAR And 3 Stocks To Watch Heading Into Friday - Galecto (NASDAQ:GLTO), AAR (NYSE:AIR)

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Galecto Inc (GLTO) Reports Topline Results from MYLOX-1 Trial Demonstrated Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Galecto Inc (GLTO) Reports Topline Results from MYLOX-1 Trial Demonstrated Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.